摘要
本文应用２株临床分离的ｍｅｃＡ基因阳性的甲氧西林高度耐药金黄色葡萄球菌９８－０１５和９８－２２２感染的小鼠败血症模型，评价美若培南与奈替米星联合方案及单药治疗的体内抗菌活性。结果表明，美若培南与奈替米星联合治疗ＭＲＳＡ９８－０１５和９８－２２２感染小鼠的ＥＤ５０分别为１１．４和１０．８ｍｇ·ｋｇ－１，显著低于单独使用美若培南（５３．４和４０．０ｍｇ·ｋｇ－１）或奈替米星（２５．２和２０．８ｍｇ·ｋｇ－１）的ＥＤ５０（Ｐ＜０．０１）。说明美若培南和奈替米星联合方案的体内抗菌活性比单药强。
An experimental model of mouse septicemia infected by two strains of mecA gene positive MRSA, S. aureus 98～015 and 98～222, isolated from clinic, was used for evaluating in vivo antimicrobial activities of meropenem and netilmicin combination regimen compared with meropenem or netilmicin alone. Results showed that ED50 of the combination of meropenem with netilmicin in the treatment of MRSA 98～015 and 98～222 infections were 11.4 and 10.8 mg·kg-1 , both were significantly lower than those of meropenem(53.4 and 40.0 mg·kg-1) and netilmicin (25.2 and 20.8 mg·kg-1) alone.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
1999年第2期113-116,共4页
The Chinese Journal of Clinical Pharmacology
